Frazier Life Sciences Management, L.P. Syndax Pharmaceuticals Inc Transaction History

Frazier Life Sciences Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$14.52 - $21.77 $45.1 Million - $67.7 Million	-3,108,838 Reduced 83.82%	600,000 $8.71 Million
Q4 2022 Feb 03, 2023	BUY	$20.64 - $26.24 $6.11 Million - $7.77 Million	296,000 Added 8.67%	3,708,838 $94.4 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $4.02 Million - $5.39 Million	217,435 Added 6.8%	3,412,838 $82 Million
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $47.4 Million - $70.8 Million	3,195,403 New	3,195,403 $55.5 Million

228

88.4M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.